MedPath

Dexamethasone Sodium Phosphate

Dexamethasone Sodium Phosphate Injection, USP

Approved
Approval ID

ce25183b-cd67-4997-8de9-df59b750883b

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Aug 16, 2023

Manufacturers
FDA

Fresenius Kabi USA, LLC

DUNS: 608775388

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Dexamethasone Sodium Phosphate

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code76045-210
Application NumberANDA203129
Product Classification
M
Marketing Category
C73584
G
Generic Name
Dexamethasone Sodium Phosphate
Product Specifications
Route of AdministrationINTRAVENOUS, INTRAMUSCULAR, INTRA-ARTICULAR, INTRALESIONAL, SOFT TISSUE
Effective DateDecember 9, 2020
FDA Product Classification

INGREDIENTS (5)

Dexamethasone Sodium PhosphateActive
Quantity: 4 mg in 1 mL
Code: AI9376Y64P
Classification: ACTIM
Citric Acid MonohydrateInactive
Code: 2968PHW8QP
Classification: IACT
Trisodium citrate DihydrateInactive
Code: B22547B95K
Classification: IACT
WaterInactive
Code: 059QF0KO0R
Classification: IACT
Sodium HydroxideInactive
Code: 55X04QC32I
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Dexamethasone Sodium Phosphate - FDA Drug Approval Details